Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 2/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.33 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.30 |
| ▸ | HTR3B | O95264 | 1/20 | 0.30 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.30 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426758 | 0.96 | DNMT1 (0.34) | DNMT1EHMT2CTSBPPP3CBELANE | |
| SCHEMBL4298045 | 0.86 | CYP3A4 (0.38) | CTSBELANEKCNH2 | |
| SCHEMBL2426760 | 0.86 | DNMT1 (0.33) | DNMT1EHMT2CTSBMAPTDHODH | |
| SCHEMBL2894467 | 0.83 | AAK1 (0.35) | DNMT1EHMT2CTSBPPP3CB | |
| SCHEMBL2429482 | 0.81 | CYP3A4 (0.38) | CTSBELANEKCNH2 | |
| SCHEMBL2897360 | 0.80 | SMN1; SMN2 (0.40) | MAPTDHODHHTR3EHTR3BHTR3A | |
| SCHEMBL2894812 | 0.80 | AAK1 (0.34) | CTSBPPP3CB | |
| SCHEMBL13026228 | 0.79 | AAK1 (0.35) | DNMT1EHMT2CTSBPPP3CB | |
| SCHEMBL8221244 | 0.77 | AAK1 (0.34) | CTSBPPP3CB | |
| SCHEMBL2754150 | 0.76 | AAK1 (0.38) | EHMT2CTSBPPP3CBELANEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | DNMT1 1017/4885EHMT2 3070/4885CTSB 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.